• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 15, 2013

View Archived Issues

Ampio Amps Up on Pain Findings in Knee Osteoarthritis

Positive findings from an initial Phase III study of pain candidate Ampion drove shares of Ampio Pharmaceuticals Inc. (NYSE:AMPE) higher Wednesday. Patients in the Phase III SPRING study in osteoarthritis of the knee (OAK) treated with a single intra-articular injection of the non-steroidal immunomodulator achieved clinically meaningful reduction in pain. Investors took notice, sending shares of the Greenwood Village, Colo.-based company up 30 percent at the opening bell. Read More

Immunomedics Reports High Efficacy for Epratuzumab Phase II

Immunomedics Inc.'s epratuzumab exceeded expectations in a Phase II trial in follicular lymphoma, producing a response rate of 88.2 percent when used in combination with rituximab. Read More

Waiting on Congress for Track & Trace Could Be a Gamble

Drugmakers that are doing nothing to prepare for California's track-and-trace requirements in the hope that Congress passes legislation to preempt the state law could be taking a big gamble. Read More

GSK Bolsters its Electroceutical Position with $50M Investment

LONDON – Glaxosmithkline plc (GSK) has put further flesh on its ambition to become a leader in electroceuticals – in which nanoscale devices will be used to modulate the body's neural circuits – with the announcement of a $50 million venture capital fund to back pioneers in the field. Read More

Grants Flow Freely in Europe; Biomedical Catalyst Leads Way

LONDON – There's been a summer bonanza of grants for European biotechs, with awards from different sources to fund projects ranging from early stage academic collaborations to running Phase II trials. Read More

Trial Deaths Prompt Some Novel T-Cell Screening Methods

Cancer immunotherapy is currently the industry's knight in shining armor. Researchers have high hopes that harnessing the immune system will enable cancer treatment to finally offer patients durable remissions or even cures, rather than the short-term respite that current cancer drugs all too often provide. Read More

Fate Therapeutics Joins Biopharma's IPO Runway

Hoping to follow in the footsteps of two other companies focused on stem cells – Verastem Inc. and Stemline Therapeutics Inc. – that successfully completed their initial public offerings (IPOs) in 2012 and 2013 respectively, San Diego-based Fate Therapeutics Inc. filed its S-1 with the SEC to raise up to $69 million in an IPO. Read More

Stock Movers

Read More

Earnings Roundup

• Savient Pharmaceuticals Inc., of Bridgewater, N.J., reported that net sales for its gout drug Krystexxa (pegloticase), were $6. 1 million for the second quarter ended June 30, a 38 percent increase over the first quarter of the year. Read More

Other News To Note

• Ligand Pharmaceuticals Inc., of San Diego, signed a license agreement with Curx Pharmaceuticals Inc., also of San Diego, to develop and commercialize Ligand's Captisol-enabled Topiramate Injection for partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate. Ligand will be eligible for more than $21 million in potential net milestone payments and net royalties on future sales of 6 percent to 7.5 percent. Read More

Clinic Roundup

• Prima Biomed Ltd., of Sydney, Australia, said the Korean Ministry of Food and Drug Safety granted approval to begin the Phase II/III CANcer VAccine Study (CANVAS) of CVac at several sites. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe